June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Subretinal fibrosis in patients with choroidal neovascularization based on spectral-domain optical coherence tomography classification: findings from the HARBOR trial
Author Affiliations & Notes
  • Sean Adrean
    Retina Consultants of Orange County, Fullerton, California, United States
  • Lauren Hill
    Genentech Inc, South San Francisco, California, United States
  • Manuel J Amador-Patarroyo
    Genentech Inc, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Sean Adrean Allergan, Amgen, Apellis, Genentech, Inc., IvericBio, NGM Biopharmaceuticals, Regeneron, RegenXBio, Code C (Consultant/Contractor), Genentech, Inc., Regeneron, Code F (Financial Support), Alimera, RegenXBio, Code R (Recipient); Lauren Hill Aerpio, Alimera, Genentech Inc., PolyPhotonix, Recens Medical , Code C (Consultant/Contractor); Manuel Amador-Patarroyo Genentech, Inc., Code E (Employment)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation. Third-party writing assistance was provided by Elizabeth Daniel, PhD, of Envision Pharma Group and funded by Genentech, Inc.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3869. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sean Adrean, Lauren Hill, Manuel J Amador-Patarroyo; Subretinal fibrosis in patients with choroidal neovascularization based on spectral-domain optical coherence tomography classification: findings from the HARBOR trial. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3869.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Clinicians increasingly use spectral-domain optical coherence tomography (SD-OCT) to diagnose and follow neovascular age-related macular degeneration (nAMD). The purpose of this analysis of pooled data from HARBOR was to evaluate rates of fibrosis from choroidal neovascularization (CNV) based on SD-OCT classification.

Methods : SD-OCT scans from the phase 3 HARBOR trial (NCT00891735) of ranibizumab in patients with nAMD were reread by Doheny Image Reading and Research Laboratory, and CNV was classified as type 1, 2, and/or 3. Month 24 fibrosis status/location by baseline CNV type were evaluated using pooled observed data.

Results : At month 24, fibrosis was present in 31% (67/216) of eyes with type 1 lesions, 53% (176/332) with type 2 lesions, 45% (120/264) with mixed type 1/2 lesions, and 33% (17/51) with any type 3 lesions (overall P < 0.0001; Figure 1). Of those eyes with subretinal fibrosis, the majority had subfoveal involvement at month 24 (% patients for each lesion type: type 1, 75%; type 2, 78%; mixed type 1/2, 73%; type 3, 65%). Results were generally similar when stratified by treatment regimen (monthly vs pro re nata [as-needed]; Figure 2).

Conclusions : These findings demonstrate that eyes with type 2 CNV lesions had higher rates of fibrosis at month 24 than those with other lesion types.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Figure 1. Month 24 Fibrosis Status by Baseline OCT CNV Lesion Classification
CNV, choroidal neovascularization; OCT, optical coherence tomography.

Figure 1. Month 24 Fibrosis Status by Baseline OCT CNV Lesion Classification
CNV, choroidal neovascularization; OCT, optical coherence tomography.

 

Figure 2. Month 24 Fibrosis Status by Baseline OCT CNV Lesion Classification by Treatment Regimen
CNV, choroidal neovascularization; OCT, optical coherence tomography; PRN, pro re nata (as-needed).

Figure 2. Month 24 Fibrosis Status by Baseline OCT CNV Lesion Classification by Treatment Regimen
CNV, choroidal neovascularization; OCT, optical coherence tomography; PRN, pro re nata (as-needed).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×